HLariboisier otholaryngology clinic
Paris, 75010, France
NCT Number: NCT03919474
The roles of thrombophilia and cardiovascular risk factors in sudden sensorineural hearing loss (SSNHL) remain controversial. Cochlear micro-thrombosis has been hypothesized as a possible pathogenic mechanism of SSNHL. The objective was thus to measure the levels of markers of macrovascular thrombosis and microvascular risk factors
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Paris, 75010, France
To recruit adult consecutive outpatients referred for SSNHL to the otolaryngologist clinic of our university hospital starting June 2016 and prospectively until december 31th 2018.
Plasma sampling and biomarkers quantification : After a 48-hours diet excluding serotonin- and tryptophan-rich food, fasting blood samples were collected into vacuum tubes containing 109 mM sodium citrate (Becton-Dickinson, Le Pont de Claix, France) with a 9:1 blood-to-anticoagulant ratio. After removing 0.5 mL of whole blood for serotonin measurements, the remainder was centrifuged at 1,000 x g for 10 minutes, and the supernatant was then centrifuged at 3,000 x g for 15 minutes to isolate platelets and obtain platelet-poor plasma. Importantly, the time between blood sampling and platelet/plasma isolation was less than one hour. Aliquots of whole blood, platelets, and plasma were kept frozen (-20°C) until serotonin and homocysteine measurements performed within one week after congelation. Whole blood, platelet and plasma 5-HT as well as plasma homocysteine (Hcy) levels were measured by high pressure liquid chromatography coupled to fluorimetric detections .
Thrombophilia screening included measurements of antithrombin , protein C, protein S, factor V Leiden, prothrombin G20210A, methylene tetrahydrofolate reductase (MTHFR) C677T, antiphospholipid antibodies anticardiolipin IgG and IgM and anti-beta2 glycoprotein 1 IgG), dilute Russell viper venom time , Rosner index, factor VIII, von Willebrand factor (vWF) activity and antigen. Tests were performed on citrated plasma, serum or DNA as appropriate and as previously described
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
follow up of microvascular biomarkers during patient follow up
Time frame: at three months and then once a year up to five years
plasma serotonin level (HPLC, frequent value <15nM)
Time frame: at three months and then once a year up to five years
plasma homocystein (HPLC, fequent value <15 µM)
Time frame: at three months and then once a year up to five years
serum anticardiolipin antiboy (ELISA, frequent value <10units)
Time frame: at three months and then once a year up to five years
audiogram
Hopital Lariboisière
Other
Markers of Microvascular Lesion in Adult Patients With Acquired Sudden Cochelo-vestibular Deficiency
Acronym: SSNHL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04349189
Anemia, Anemia, Hemolytic
Bethesda, Maryland, United States
View Trial DetailsNCT03682419
Antiphospholipid Syndrome, Arrhythmias, Cardiac
Glasgow, United Kingdom
View Trial DetailsNCT07342127
Factor II Heterozygous Mutation, Factor V Leiden Heterozygous Mutation
Bron, France
View Trial DetailsNCT06133621
Antiphospholipid Syndrome, Autoimmune Diseases
Lyon, France
View Trial Details